Oncolytics Biotech (TSE:ONC) Director Deborah Brown Acquires 25,000 Shares

Oncolytics Biotech Inc. (TSE:ONC) Director Deborah Brown acquired 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 12th. The stock was purchased at an average cost of C$1.17 per share, with a total value of C$29,250.00. Following the purchase, the director directly owned 109,851 shares in the company, valued at approximately C$128,525.67. This trade represents a 29.46% increase in their position.

Oncolytics Biotech Stock Performance

Shares of ONC stock opened at C$14.90 on Friday. Oncolytics Biotech Inc. has a 1-year low of C$0.44 and a 1-year high of C$2.08. The company has a current ratio of 2.99, a quick ratio of 8.86 and a debt-to-equity ratio of 11.75. The company has a market capitalization of C$1.50 billion, a price-to-earnings ratio of -40.27 and a beta of 0.80. The stock’s fifty day simple moving average is C$14.90 and its 200-day simple moving average is C$13.03.

Oncolytics Biotech (TSE:ONC) last announced its quarterly earnings data on Wednesday, November 12th. The company reported C($0.14) earnings per share (EPS) for the quarter. On average, sell-side analysts predict that Oncolytics Biotech Inc. will post -0.41 earnings per share for the current fiscal year.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.